Biodesix Stock Dips Following Analyst's Downgrade

Biodesix shares are trading lower after Scotiabank cut its price target on the stock from $3 to $2 while maintaining an Outperform rating due to a Q1 revenue miss and FY25 revenue guidance reduction.